Your Article Summary
See Latest ArticlesImpact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis
Arthritis Care and Research , 06/09/09
Polinski JM et al. - Most MRDD beneficiaries with RA enrolled in Part D. Although plans assume some costs for biologic DMARDs, the majority of costs are shifted to beneficiaries and to Medicare. Such cost shifting may place these medications out of the beneficiary's financial reach and expose Medicare to high financial liability.
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Medicare/Medicaid...keeping you current
Receive free subspecialty "5-minute updates" via email
HHS employs new tougher standards in calculation of improper medicare payment rates for 2009
Centers for Medicare & Medicaid Services Press, 12/04/09
House approves Medicare doc fix
American Hospital Association News, 12/03/09
Iowa to receive federal matching funds for electronic health record incentives program
Centers for Medicare & Medicaid Services Press, 12/03/09